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Abstract
Depression is a debilitating disorder that can cause motivational deficits such as psychomotor
retardation, anergia, apathy, and fatigue. Recent research indicates that these motivational
deficits, and potential pathways of therapeutic intervention, can be studied in animal models
involving rats and mice. Treatments with the VMAT-2 inhibitor tetrabenazine (TBZ) and
cytokine interleukin-1ß (IL-1ß) can create a low-effort bias and impair effort-related motivation
(Nunes et al. 2013, 2014). A number of high-affinity DA transport inhibitors such as damphetamine, methylphenidate, and cocaine can restore extracellular DA, albeit with the cost of
undesirable effects such as high abuse liability. These observations have led researchers to
identify a number of molecules that fit the profile of “atypical” dopamine binding, which leads to
a longer duration of extracellular DA and minimizes side effects. In this review, the binding
affinities and dose-response behavioral outputs for respective FR5/Chow and PROG/Chow
feeding procedures have been compiled for eight DAT blockers: bupropion, GBR12909,
lisdexamfetamine, PRX-14040, modafinil, (S)-CE-123, (S, S)-CE-158, and methylphenidate.
Regression analyses between measures of DAT affinity and minimum significant dose in
behavioral studies suggests a strong linear relationship between binding affinity and potency in
terms of the ability of drugs to reverse the effects of TBZ the FR5/chow procedure. However,
there was a variable relationship in terms of the ability of drugs to enhance lever pressing in rats
tested on the PROG/choice procedure.
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Introduction
Motivated behavior is recognized to have directional aspects (i.e., behavior is directed towards
and away from stimuli), but it also has activational aspects related to behavioral activation and
exertion of effort in work output. Organisms often make effort-based decisions as they weigh the
costs and benefits of the various options in the environment. One of the ways that effort-related
aspects of motivation can be assessed is through tests of effort-based choice, in which animals
are given a choice between a preferred reinforcer that can only be obtained by high exertion of
effort, vs. a low effort/low reward option. Studies have shown that the vesicular monoamine
transport (VMAT-2) inhibitor tetrabenazine (TBZ) or the cytokine interleukin-1β (IL-1β) can
cause profound motivational impairments and shift choice behavior in rats, producing a loweffort bias (Nunes et al., 2013; Yohn et al. 2016). TBZ acts by blocking vesicular storage and
depleting dopamine (DA), as assessed by both pre- and postsynaptic markers of DA transmission
(Nunes et al. 2013). In fact, the effects of TBZ in humans can even result in the emergence of
negative symptoms such as fatigue, pointing to its potential in creating a challenge for rats to
exert physical effort when presented with a choice (Chitnis and Karunapuzha, 2009; Frank,
2010; Chen et al., 2012; Rotolo et al., 2020). In response to TBZ administration, rats demonstrate
a decreased selection of the high effort options and increased selection in low effort/low energy
options. This is possibly related to the induction of depression-like symptoms. Using an FR5 or
PROG chow feed task model, the behavioral outputs of several 5-HT selective serotonin
reuptake inhibitors (SSRI) and DA transport (DAT) inhibitors can be studied for a potential
reversal of the effects of TBZ (Yohn et al. 2016).
Rats have become a useful model organism to test the effects of commonly prescribed
antidepressants that are SSRIs, such as Lexapro (S-citalopram) and Prozac (fluoxetine), which
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are typical treatments of depression and generalized anxiety. Recent FR5 and PROG chow feed
task trials with (S)-citalopram and fluoxetine, however, have yielded no significant reversal of
the effects of TBZ (Salamone et al. 2018). In fact, these serotonin transport inhibitors even have
the tendency to exacerbate symptoms and produce further impairments in level pressing such as
fatigue (Yohn et al., 2016). These data point to the inefficiency of common market SSRIs in
battling motivational symptoms in patients. Since SSRIs selectively inhibit serotonin reuptake
pathways, research suggests that the dopamine transporter is associated with a critical pathway in
cost/benefit analysis and effort-related decision making (Nunes et al., 2013; Yohn et al. 2016).
A number of DAT inhibitors have been tested by Salamone and colleagues (Nunes et al. 2013;
Randall et al. 2015; Yohn et al. 2016; Rotolo et al. 2019, 2020, 2021). For the present study, a
select number of reversal agents that directly act on the nucleus accumbens core DA transporter
were investigated for their respective binding affinities and dose-response outputs (Salamone and
Correa, 2002, 2012; Salamone et al, 2003, 2007; Nunes et al, 2013). These DAT inhibitors
(bupropion, GBR12909, lisdexamfetamine, PRX-14040, modafinil, (S)-CE-123, (S, S)-CE-158,
and methylphenidate) are all highly selective for DAT binding relative to the serotonin
transporter, and some are selective vs. norepinephrine transport binding as well. Affinity more
specifically refers to the strength of the tendency of a neurotransmitter or ligand to bind to its
protein target, whether a receptor or a transporter. Intrinsic quantitative measures such as Ki,
Km, Kapp or IC50 can represent affinity as the concentration of a ligand that yields 50% of
maximal transporter binding. Transporter binding is central to determining drug affinity for
drugs that act on the uptake process, yet potency in terms of behavioral effects incorporates other
factors such as metabolism, penetration into the tissue of interest, and the duration of action. The
doses at which a drug has its effect and its molecular affinity are typically correlated as long as
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these other factors are relatively equal, so the present study seeks to identify a link for each DAT
inhibitor on both FR5 and PROG operant procedures. After compiling DAT binding affinity
(nM) values and calculating lowest significant doses (mg/kg) for behavioral effects in rats tested
on FR5 and PROG procedures, a statistical regression analysis was conducted to determine the
line of best fit and the Pearson product-moment correlation coefficient, the proportion of
variability accounted for, and the standard error of estimate around the regression line. These
analyses can be used to further clarify the relation between binding to the DAT as measured in
vitro and the behavioral effects of these drugs.

Materials and Methods
Animals
For the behavioral studies (Nunes et al. 2013; Randall et al. 2015; Yohn et al. 2016; Rotolo et al.
2019, 2020, 2021), protocols were approved by the University of Connecticut Institutional
Animal Care and Use Committee (IACUC). Adult male Sprague Dawley rats (Indianapolis, IN,
USA) were housed at 23 °C during 12 hour light/dark cycles (e.g. Yohn et al., 2016). The
animals generally weighed approximately 300 grams at the beginning of each study. Although
initially, food was restricted to 85% of their body weight, these rats were later fed supplemental
lab chow and provided water ad libitum to allow gradual growth. Animal protocols followed
National Institute of Health (NIH) guidelines (e.g. Nunes et al., 2013).

Concurrent FR5/Chow-choice Procedure
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The concurrent FR5/chow-choice procedures were conducted in operant conditioning chambers,
where rats were first trained to lever press with continuous reinforcement. These sessions were
generally 30 minutes over 5 days, after which the rats were shifted to an FR5 schedule (30 min
sessions, 5 days/week). After training for several weeks until reaching a baseline target for lever
presses, the rats were finally introduced to the concurrent FR5/chow feeding choice procedure.
This procedure is conducted in the operant chamber by making a low-reward lab chow and a
high-carbohydrate reinforcer accessible via lever pressing during the 30-minute session. While
both options are available, the rats are able to choose their behavior towards either the chow or
the high carb pellet. Before starting the session, it was ensured that the weighted chow pieces
would not fall through the floor of the chamber (e.g. Rotolo et al., 2019). At the start of each
session, it was confirmed that the pieces of weighed chow were larger than the spaces between
the bars that make up the floor of the chamber, so they could not fall through. After each session
completed, each rat was removed from the chamber while the number of lever presses and
consumed chow weight (calculated from spillage) was recorded (e.g. Yohn et al., 2016).

PROG/Chow Feeding Choice Task
In contrast to the concurrent FR5 procedure, the lever-pressing option will end in the
PROG/chow-feeding choice procedure within 2 minutes if the rat fails to obtain a reinforcer,
meaning that the chow will become the only option after this interval (Salamone et al., 2018).
This “time-out” would result from the deactivation of the response lever for the rest of the
session when the 2-minute interval completed without a completed ratio (Rotolo et al., 2019).
For this procedure, rats were first trained on a continuous reinforcement FR1 schedule followed
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by a shift to a PROG schedule, where the ratio from the FR1 was gradually increased. After
several weeks of training on the PROG schedule, weighted amounts of lab chow become
available in the chamber during PROG/chow feeding choice task sessions (generally 30 minutes
each). Similar to the FR5 procedure, the number of lever presses and amount of chow consumed
were recorded at the end of each session. After training on the concurrent FR5/chow-choice and
PROG/chow feeding choice procedures for several weeks, novel drug testing was introduced
respectively.

Dose Selection
Novel atypical molecules obtained by Salamone Lab were generally dissolved in dimethyl
sulfoxide (DMSO) and saline solution with the DMSO/saline solution serving as vehicle control,
or in physiological saline. Tetrabenazine was received from Tocris Bioscience (Ellisville, MO)
and titrated with extremely small quantities of 1.0 N HCl to achieve an overall pH of 4.5. The
dosage of TBZ was typically calculated to be 0.75 mg/kg-1.0 mg/kg TBZ based on extensive
piloting and previous work in the laboratory. Doses of reversal agents were also determined
based on previous research and rodent runaway studies (Sink et al., 2008; Esumi et al., 2013).

Statistical Analysis
DAT affinity values were extensively searched through neuropsychopharmacology literature
using the electronic database PubMed, as listed in Table 1. These data were calculated via in
vitro binding or inhibition assays (Cao et al., 2016; Zhang et al., 2017). In each behavioral
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pharmacology paper, rats received vehicle or 0.75mg/kg TBZ approximately 90 minutes before
testing followed by intraperitoneal injections of vehicle or the DAT blocker at varying times
before behavioral testing, depending upon the drug (Salamone et al., 2016; Rototol et al. 2019,
2020, 2021). Statistical analyses were used in each paper to identify the doses of a DAT blocker
plus TBZ that significantly increased lever pressing relative to TBZ plus vehicle (P<0.05). The
potency values for the regression analyses for each DAT inhibitor were calculated by identifying
the lowest significant dose based on the minimum dosage that significantly differed from TBZ
plus vehicle. A complete list of binding affinity (nM) and lowest significant doses (mg/kg) for all
eight DAT blockers used in the TBZ studies is depicted in Table 2. GraphPad Prism 8.4.1 was
used to compute a regression analysis determining a linear relationship between affinity and
potency for both concurrent FR5 and PROG chow choice procedures (Figure 1). Recently
synthesized atypical DAT inhibitor CT-005404 (Chronos Therapeutics) was excluded from this
study as doses were administered orally rather than intraperitoneally (Rotolo et al., 2020).
Modafinil was studied for its effects on FR5/chow feeding choice performance but never for its
ability to reverse choice-induced shifts of TBZ on the PROG/chow feeding procedure (Salamone
et al., 2016). For this reason, it was included in the DAT vs. FR5 statistical analysis (n=8) but
excluded from the DAT vs. PROG calculations (n=7).

Results
Bupropion
The commonly prescribed antidepressant bupropion was extensively studied in the Nunes et al.
2013 study with IP injections of Vehicle/Vehicle, 0.75 mg/kg TBZ/Veh, or TBZ coadministered
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with doses of bupropion (5.0, 10.0, or 15.0 mg/kg doses). Compared to the administration of
TBZ alone, catecholamine uptake inhibitor bupropion was able to significantly reverse the
effects of tetrabenazine. The highest doses of bupropion increased lever presses over a 30-minute
session and decreased intake of freely available laboratory chow.
In the Yohn et al. 2016 study, however, the selective DA D1 antagonist SCH 39166 (ecopipam)
and DA D2 antagonist haloperidol were capable of blocking its reversal of TBZ depressive
effects. Although these antagonists had no effects when administered alone, the coadministration
of either 0.05 mg/kg of ecopipam or 0.05 mg/kg haloperidol significantly reduced the efficacy of
bupropion.

GBR12909
Originally developed as a potential treatment for cocaine addiction, GBR12909 shows a much
lower efficacy than cocaine and atypical binding properties (Yohn et al., 2016). More than a 100fold lower in NET and SERT affinity (Anderson, 1989), GBR12909 is one of many benztropine
analogs that have been associated with increased DA levels in nucleus accumbens for a longer
duration than cocaine. In an experiment in the Yohn et al. 2016 study, trained rats received the
following treatments of TBZ vehicle plus GBR12909 vehicle: 0.75 mg/kg TBZ + GBR12909
vehicle, 0.75 mg/kg TBZ + 1.25 mg/kg GBR12909, 0.75 mg/kg TBZ + 2.5 mg/kg GBR12909,
and 0.75 mg/kg TBZ + 5.0 mg/kg GBR12909. The results showed that the highest doses of
GBR12909 + TBZ vehicle (2.5 and 5.0 mg/kg of GBR12909) were statistically significant
(P<0.05) from the TBZ vehicle, leading to a significantly lower chow consumption.
Additionally, when administered without TBZ on a concurrent FR5/chow-choice procedure, the
highest doses of GBR12909 yielded significantly higher lever presses than NET inhibitor
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desipramine and SERT inhibitor fluoxetine. The results of this study demonstrate that
GBR12909 successfully attenuates TBZ-induced shifts in rat behavior, and it is a more powerful
reversal agent than norepinephrine and serotonin transport inhibitors.

LDX
Lisdexamfetamine (LDX) is a novel descendant of d-amphetamine which has been approved for
the treatment of attention deficit hyperactivity disorder (ADHD) and binge eating disorder in
adults (Weisler et al. 2009; FDA News Release 2015). While d-amphetamine is known to cause
sudden bursts in extracellular catecholamine levels, LDX leads to a much longer duration of
these neurotransmitter levels, especially high concentrations of dopamine in the nucleus
accumbens. The ability of LDX to increase effort in rats treated with cytokine interleukin-1ß,
TBZ, and TBZ + CIT was studied on a concurrent FR5/chow-feeding procedure. IL-1ß is
associated with depressive symptoms in humans and has shown to reduce the selection of high
effort alternatives and increase consumption of lab chow in rat models. In the Yohn et al. 2016
study of LDX, the ability of LDX to ameliorate the effects of IL-1ß was experimented with the
following dosage: IL-1β-vehicle + LDX vehicle, 4.0 μg/kg IL-1β- + LDX vehicle, 4.0 μg/kg IL1β- +0.09375 mg/kg LDX, 4.0 μg/kg IL-1β- + 0.1875 mg/kg LDX, 4.0 μg/kg IL-1β- + 0.375
mg/kg LDX, and 4.0 μg/kg IL-1β- + 0.75 mg/kg LDX. The treatment of 0.09, 0.375 and 0.75
mg/kg of LDX with IL-1ß significantly increased lever pressing and decreased chow
consumption compared to IL-1ß alone. Similarly, the ability of LDX to attenuate the behavioral
effects of TBZ treatment was investigated on the same procedure with the following dosage:
TBZ vehicle + LDX vehicle, 0.75 mg/kg TBZ + LDX vehicle, 0.75 mg/kg TBZ + 0.09375
mg/kg LDX; 0.75 mg/kg TBZ + 0.1875 mg/kg LDX, 0.75 mg/kg TBZ + 0.375 mg/kg LDX, and
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0.75 mg/kg TBZ + 0.75 mg/kg LDX. Similar to the results of the IL-1ß experiment, LDX
successfully attenuated the effects of TBZ with the coadministration of 0.1875, 0.375, and 0.75
mg/kg LDX being statistically significant (P<0.05). In all three treatments, LDX plus TBZ
significantly increased lever pressing and decreased chow consumption, indicating a full
reversal.

PRX-14040
Novel DA update inhibitor PRX-14040 was introduced as a transporter with low molecular
weight and Log P values yet an optimal atypical DA selectivity. While PRX is able to bind to
both dopamine and norepinephrine transporters, it shows a 28-fold higher selectivity for the
dopamine transporter (Yohn et al., 2016). The Yohn et al. (2016) PREXA study analyzed the
ability of PRX to both reverse the TBZ shifts in behavior on the FR5/chow choice task and
increase lever pressing in the PROG/chow choice task. On the FR5 procedure, trained rats
received the following dosage: TBZ vehicle + PRX vehicle, 0.75 mg/kg TBZ + PRX vehicle,
0.75 mg/kg TBZ + 1.25 mg/kg PRX, 0.75 mg/kg TBZ + 2.5 mg/kg PRX, 0.75 mg/kg TBZ + 5.0
mg/kg PRX, and 0.75 mg/kg TBZ + 10.0 mg/kg PRX. Overall, PRX yielded a complete reversal
of the effects of TBZ with the co-administration of 2.5, 5.0, and 10.0 mg.kg PRX significantly
increasing the number of lever presses and increasing chow consumption relative to the TBZ
vehicle group (P<0.0001). In the PROG/chow choice task, trained rats were IP injected with
doses of 5.0, 10.0, 20.0, and 40.0 mg/kg PRX an hour before testing. The results revealed that
the administration of 10.0, 20.0 and 40.0 mg/kg PRX significantly increased the total number of
lever presses, achieved the highest ratio relative to vehicle treatment (F(4.36) = 12.075), and
decreased consumption of lab chow (P<0.05). PRX also yielded the highest reversal effect size
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(partial ε2) for TBZ-induced reversal of suppression in lever pressing and increase in chow
intake relative to bupropion, modafinil and methylphenidate. The unique DA binding selectivity
of PRX, compared to other drugs such as BUP, MOD, and MET, improves its candidacy as a
treatment of motivational dysfunction.

Modafinil
Modafinil, or MOD, is a wakefulness agent that has already been used in clinical studies to treat
depressive-like symptoms such as fatigue and anergia. The Rotolo et al. 2019 study compared
modafinil to its analog (S)-CE-123. While MOD demonstrates improvement in fatigue and
reversal of low-effort bias, it requires higher doses on the FR5 procedure than analogs with
highly selective DA binding. Despite its low affinity in the reversal of depressive symptoms,
MOD demonstrates a low abuse liability. As mentioned earlier, modafinil was not tested for its
potential to reverse effects of TBZ on the PROG procedure.

(S)-CE-123
Novel atypical DA transport inhibitor (S)-CE-123 is a synthesized analog of modafinil with a
highly selective affinity for DAT. The Rotolo et al. 2019 study has not only demonstrated its
ability to reverse TBZ-induced shifts in rats, but also its enhancement of cognitive flexibility and
reduction of impulsivity and undesirable effects. In the study, trained rats were administered the
following combinations of (S)-CE-123 and TBZ: TBZ vehicle + (S)-CE-123 vehicle, 1.0 mg/kg
TBZ + (S)-CE-123 vehicle, 1/0 mg/kg TBZ + 6.0 mg/kg (S)-CE-123, 1.0 mg/kg TBZ + 12.0
mg/kg (S)-CE-123, and 1.0 mg/kg TBZ + 24.0 mg/kg (S)-CE-123. The coadministration of 24.0
mg/kg (S)-CE-123 significantly increased total lever presses and decreased chow consumption.
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Although the administration of (S)-CE-123 alone had no effect on lever pressing or chow
consumption, it significantly increased the DA levels in the nucleus accumbens core (P<0.05).

(S, S)-CE-158
(S, S)-CE-158 is a novel atypical analog of modafinil, similar to its stereoisomer, thiazole-based
(S)-CE-123, in its specificity of its DA inhibition. While (S)-CE-123 has demonstrated procognitive effects and preclinical effectiveness without adverse side effects, (S, S)-CE-158 and a
range of modafinil-related drugs have been included in the investigation to identify the most
promising candidate to treat motivational dysfunction (Nikiforuk et al. 2017; Kalaba et al. 2017;
Kristofova et al. 2018; Camats-Perna et al. 2019). In the Rotolo et al. 2020 study, rats were
administered five treatment options: TBZ vehicle + (S, S)-CE-158 vehicle; 1.0 mg/kg TBZ + (S,
S)-CE-158 vehicle; 1.0 mg/kg TBZ + 2.0 mg/kg (S, S)-CE-158; 1.0 mg/kg TBZ + 4.0 mg/kg (S,
S)-CE-158; 1.0 mg/kg TBZ + 8.0 mg/kg (S, S)-CE-158. The co-administration of 8.0 mg/kg (S,
S)-CE-158 plus TBZ yielded a significant increase in lever pressing and decrease in chow intake
compared to TBZ plus vehicle (P<0.001). Repeated measures ANOVA identified a significant
increase in lever pressing and high-effort responding on the concurrent PROG/chow feeding
choice procedure at a co-administered minimum dose of 4.0 mg/kg (S, S)-CE-158 plus TBZ
compared to TBZ plus vehicle (P<0.01).
Methylphenidate
Methylphenidate, or MET, is a stimulant drug with DA reversal properties that has been
commonly tested in human clinical populations. In the Yohn et al. 2016 PREXA study, the coadministration of MET with TBZ in rats successfully attenuated the effects of TBZ alone, but it
resulted in similar comparisons as modafinil. Compared to the co-administration of PRX and
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BUP, MET yielded significantly lower lever presses on the FR5 procedure. Although
methylphenidate improves motivational deficits by inhibiting the dopamine transporter (DAT),
its stimulant nature also results in a number of undesirable side effects such as strong abuse
liability and psychotic symptoms (Rotolo et al., 2019).

DAT Blocker

Affinity Value

Citation

Bupropion

Ki = 630nM

(Meyer et al., 2002; Richelson
and Pfenning 1984; Tatsumi
et al. 1997; Schmitt et al.,
2008)

GBR12909

Kapp = 121∓ 21nM

(Schmitt et al., 2008;
Vladimir et al., 2008)

LDX

Km = 200nM

(Yohn et al., 2016)

PRX-14040

Ki = 9.43nM

(Yohn et al., 2016; Gu et al.,
1994; Giros and Caron, 1993;
Galli et al., 1995; Shearman
et al., 1998)

Modafinil

Km = 3050 ∓ 258nM

(Salamone et al., 2016; Zhang
et al. 2017)

(S)-CE-123

IC50 = 4.6 µM

(Sagheddu et al., 2020)

(S, S)-CE-158

IC50 = 0.2271μM

(Rotolo et al., 2020)

Methylphenidate

IC50 = 224 ∓ 19nM

(Salamone et al., 2016;
Wayment et al., 1999)
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Table 1. List of dopamine transport inhibitors from selective literature and corresponding
affinity values (nM).

FR5 (mg/kg)

DAT (nM)

PROG (mg/kg)

BUP

10

630

20

GBR12909

2.5

121

5

LDX

0.1875

200

0.75

PRX-14040

2.5

9.43

20

MOD

7.5

3050

(S)-CE-123

24

4606

24

(S, S)-CE-158

8

227

4

METH

0.5

224

4

BUP = bupropion; LDX = lisdexamfetamine; MOD = modafinil; METH = methylphenidate

Table 2. List of lowest effective doses (mg/kg) calculated from FR5 and PROG dose-response
curves and corresponding DAT affinities (nM).
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Figure 1. A) Scatterplot with regression line (solid line) and 95% confidence intervals (dotted
curves) showing the relation between affinity of DA transport blocker vs. its minimum effective
dose on concurrent FR5/Chow-choice Procedure. R2 = 0.7089 and the graph has a 95%
confidence interval of (0.3376, 0.9707) with a standard error of estimate (sYX) of 4.599. B)
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Scatterplot with regression line (solid line) and 95% confidence intervals (dotted curves)
showing the relation between affinity of dopamine transport blocker against its minimum
effective dose on PROG/Chow Feeding Choice Task. R2 = 0.3687 and the graph has a 95%
confidence interval of (-0.2687, 0.9334) with a sYX of 8.483.

Discussion
In determining the “goodness of fit” on a correlational analysis, the coefficient of determination
(R2) and standard error of estimate (sYX) are common indicators. Variance, or the scatter around
the line of best fit, refers in this study to the minimum dose values (mg/kg) that can be predicted
by DAT affinity values (nM). The R2 calculations of both graphs indicate that 71% of the
variance in data can be explained in the concurrent FR5 procedure (Figure 1A), yet only 37%
can be explained in the concurrent PROG procedure (Figure 1B). The 95% confidence bands
also demonstrate a larger gap in variance on the PROG interval of (-0.2687, 0.9334) compared to
the FR5 interval of (0.3376, 0.9707). The standard error of estimate, or sYX, measures both the
variability of the observed scatter and reliability of the estimating equation (Y=mx+b). The
predicted sYX value for DAT vs FR5 is 4.599, nearly half the DAT vs PROG value of 8.483.
The strength of the correlation between affinity and behavioral potency can be characterized with
significantly less dispersion on the FR5 procedure relative to the PROG procedure.
The Pearson product-moment correlation coefficient (r) captures linear relationships on a range
of -1 to +1, corresponding to negative and positive slopes respectively. An absence of a linear
pattern falls closer to a value of 0. GraphPad Prism 8.4.1 computed r = 0.8420 for Figure 1A and
r = 0.6072 for Figure 1B, indicating stronger linearity on the FR5 procedure relative to the
18

PROG procedure. A computational two-tailed hypothesis test (α = 0.05) yielded a p-value of
0.0087 for DAT vs FR5 and a p-value of 0.1482 for DAT vs PROG. For the regression graph of
FR5, P<0.05 and the null hypothesis can be rejected, concluding a strong linear correlation
between the variables. The PROG data, however, fails to reject Ho in favor of Ha (P>0.05) and
lacks substantial evidence to conclude a linear relationship. The correlation between the dose at
which a DAT blocker has its effect and its unique binding affinity can be summarized as
statistically significant for the FR5/chow choice task, but not conclusive for the PROG/chow
choice task.
The increased variability in PROG dispersion compared to that of the FR5 procedure could be
partially attributed to its exclusion of modafinil, reducing its total drug count to n = 7. The drugs
selected for this study consist of both typical and atypical DA transport blockers. Atypical
analogs of modafinil such as (S)-CE-123 and (S, S)-CE-158 indicate a better profile for reversing
depression-like symptoms while decreasing potential side effects. In addition to DAT affinity,
the selectivity and binding locus of a DAT blocker have profound effects on DAT trafficking and
the ability to reduce abuse liability and psychotic symptoms (Rotolo et al., 2019). The correlation
in this study is strictly between drug affinity and potency; there is no noticeable distinction based
on binding selectivity.
In summary, there is a strong relationship between the concentration at which these various DAT
inhibitors affect DA transport in vitro and the doses at which the same compounds reverse the
effects of TBZ in vivo in rats responding on the FR5/chow feeding choice task. However, the
results regarding the PROG task were inconclusive. Future studies may consider drafting more
candidates for the regression analysis on the PROG procedure and investigating differences
between atypical or typical binding in relation to potency. Ongoing research on this topic could
19

provide insight on dosage in the therapeutic administration of pharmacological agents used to
treat motivational dysfunction and psychomotor challenges.
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